[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
OBJECTIVE
To investigate the expression and significance of u-PA, u-PAR and PAI-2 mRNA in giant cell tumor of bone.


METHODS
The expressions of u-PA, u-PAR and PAI-2 mRNA in 42 patients with giant cell tumor(GCT) of bone was detected with in situ hybridization.


RESULTS
The expression rates of u-PA, u-PAR, and PAI-2 mRNA of multinuclear giant cells (MGC) were 64.3%, 71.4% and 40.5%. Their expression rates in the mononuclear cells (MC) were 54.8%, 45.2% and 9.5%, respectively. The expression rates of u-PA mRNA in MGC, u-PA and u-PAR mRNA in MC of grade II and III lesions were significantly higher than those of grade I and non-recurrent lesions (P < 0.05). Close positive relation was observed between the expressions of u-PA mRNA of both cells, between the expressions of u-PAR and PAI-2 mRNA in MGC and also between the expressions of u-PA and u-PAR mRNA in MC. The expression rate in MGC was higher than that of MC significantly (P < 0.05).


CONCLUSIONS
The expressions of u-PA, u-PAR mRNA of giant cell tumor, especially in the mononuclear cells demonstrate lower differentiation and recurrent potential in giant cell tumor of bone. Mononuclear cells may be the main tumor cell in giant cell tumor of bone.
Li
H
H
Department of Pathology, Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou 510120, China.
Dong
S
S
Zeng
Y
Y
D001859:Bone Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D015870:Gene Expression; D018212:Giant Cell Tumor of Bone / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D015726:Giant Cells / Q000378:metabolism; D006801:Humans; D017403:In Situ Hybridization; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D009367:Neoplasm Staging; D017396:Plasminogen Activator Inhibitor 2 / Q000235:genetics*; D012333:RNA, Messenger; D011956:Receptors, Cell Surface / Q000235:genetics*; D055293:Receptors, Urokinase Plasminogen Activator; D012008:Recurrence; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics*
C524898:PLAUR protein, human; D017396:Plasminogen Activator Inhibitor 2; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator